AryoGen Pharmed (Persian: آریوژن فارمد) is an Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.^[1][2][3]

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) A major contributor to this article appears to have a close connection with its subject. (February 2017) This article needs additional citations for verification. (February 2017)

Quick Facts Company type, Industry ...

AryoGen

Company type	Private Company
Industry	Pharmaceutical
Founded	2009
Headquarters	Tehran , Iran
Area served	Worldwide
Key people	Fereidoun Mahboudi Chairman
Products	biopharmaceuticals, Monoclonal antibody
Revenue	US$ 100 million
Number of employees	300+ (2015)
Website	AryoGen

Close

AryoGen is a biopharmaceutical company created on the mandate of Iranian executive branch. It was spun off a Biopharmaceutical company, which formed a new entity named AryoGen Pharmed which started its production in 2011. It was deemed an issue of national interest. AryoGen changed its name to AryoGen Pharmed in 2016.

AryoGen Pharmed (AryoGen) has received a Good Manufacturing Practice (GMP) certificate from the European Medicines Agency (EMA), becoming one of the first monoclonal antibody (mAb) manufacturers in the Middle East and North Africa (MENA) region to be certified.^[4]

AryoGen's products include:

• Blood Coagulation factor VII with the name of AryoSeven
• Altebrel with the generic name of Etanercept and original trade name of Enbrel
• Zytux with the generic name of Rituximab and original trade name of Rituxan
• َAryoTrust with the generic name of trastuzumab and original name of Herceptin
• Stivant with the generic name of bevacizumab and original trade name of Avestin

AryoSeven is now approved by Iranian food and drug organisation and from August 2012 is in the market.

• Healthcare in Iran